1. Home
  2. COCP vs NVNO Comparison

COCP vs NVNO Comparison

Compare COCP & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COCP
  • NVNO
  • Stock Information
  • Founded
  • COCP 2006
  • NVNO 1987
  • Country
  • COCP United States
  • NVNO United States
  • Employees
  • COCP N/A
  • NVNO N/A
  • Industry
  • COCP Biotechnology: Pharmaceutical Preparations
  • NVNO Medical/Dental Instruments
  • Sector
  • COCP Health Care
  • NVNO Health Care
  • Exchange
  • COCP Nasdaq
  • NVNO Nasdaq
  • Market Cap
  • COCP 15.4M
  • NVNO 16.7M
  • IPO Year
  • COCP N/A
  • NVNO N/A
  • Fundamental
  • Price
  • COCP $1.07
  • NVNO $0.64
  • Analyst Decision
  • COCP Strong Buy
  • NVNO
  • Analyst Count
  • COCP 1
  • NVNO 0
  • Target Price
  • COCP $6.00
  • NVNO N/A
  • AVG Volume (30 Days)
  • COCP 197.1K
  • NVNO 233.6K
  • Earning Date
  • COCP 11-14-2025
  • NVNO 10-31-2025
  • Dividend Yield
  • COCP N/A
  • NVNO N/A
  • EPS Growth
  • COCP N/A
  • NVNO N/A
  • EPS
  • COCP N/A
  • NVNO N/A
  • Revenue
  • COCP N/A
  • NVNO N/A
  • Revenue This Year
  • COCP N/A
  • NVNO N/A
  • Revenue Next Year
  • COCP N/A
  • NVNO N/A
  • P/E Ratio
  • COCP N/A
  • NVNO N/A
  • Revenue Growth
  • COCP N/A
  • NVNO N/A
  • 52 Week Low
  • COCP $1.00
  • NVNO $0.62
  • 52 Week High
  • COCP $3.26
  • NVNO $5.62
  • Technical
  • Relative Strength Index (RSI)
  • COCP 43.45
  • NVNO 30.20
  • Support Level
  • COCP $1.06
  • NVNO $0.63
  • Resistance Level
  • COCP $1.15
  • NVNO $0.69
  • Average True Range (ATR)
  • COCP 0.07
  • NVNO 0.06
  • MACD
  • COCP 0.01
  • NVNO 0.02
  • Stochastic Oscillator
  • COCP 23.54
  • NVNO 18.99

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: